Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
HRL$22.98+0.22(+0.97%)3 Dividend Aristocrats Trading Below Their Historical Valuations8:34:12 AM ETTSM$385.99-9.63(-2.43%)TSMC's AI Opportunity Is Expanding. Here's the Question That Matters for Its Stock Price8:33:37 AM ETHD$359.57+4.13(+1.16%)Three Days, 36 Hands-On Workshop Sessions and HGTV's Biggest Stars: Here's What's Happening Each Day at the First-Ever DIY CON November 6-88:33:00 AM ETMCD$281.70+1.48(+0.53%)McDonald's Q3: 11% EPS Growth And A 50% Operating Margin Say The Sell-Off Was A Mistake8:30:51 AM ETTMO$711.10+4.94(+0.70%)Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance8:30:16 AM ETAAPL$353.87+4.36(+1.25%)Apple Stock Is Up 22%, but 1 Slowing Business Could Test That Valuation8:30:00 AM ETBRK-A$881,000.00+11,699.24(+1.35%)Two in three US-listed companies pay no dividend, a census of SEC filings finds8:30:00 AM ETTEAD$0.20-0.07(-25.93%)Ad platform Teads misses Q3 revenue estimates; suspends guidance8:29:01 AM ETC$126.74+1.97(+1.58%)UPDATE 6-Oil rises as investors weigh uncertainties around Iran war8:27:07 AM ETMCD$281.70+1.48(+0.53%)McDonald's To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Thursday8:22:06 AM ETMRNA$257.70-0.64(-0.25%)Moderna, Humana and Elanco Earnings Previews: What Investors Should Watch8:18:32 AM ETQCOM$154.50-18.69(-10.79%)Qualcomm: The AI Boom's Biggest Casualty8:18:20 AM ETAMD$465.43-23.35(-4.78%)AMD: The Bigger Earnings Opportunity Starts In 20278:17:47 AM ETV$440.30+3.71(+0.85%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.70+0.71(+0.89%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$138.70+1.76(+1.29%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$759.77-35.69(-4.49%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ETGOOG$290.68+3.38(+1.18%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$138.70+1.76(+1.29%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETTCPC$4.30-0.08(-1.83%)BlackRock TCP Capital Corp. Announces Third Quarter 2026 Financial Results Including Net Investment Income of $0.16 Per Share; Declares a Fourth Quarter Dividend of $0.17 Per Share8:05:07 AM ETINTC$57.08-1.20(-2.06%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,457.43-38.71(-2.59%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$317.92-7.78(-2.39%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.65+0.48(+1.04%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ET

SCYX · NASDAQ

SCYNEXIS, Inc.

$3.66 -0.19 (-4.81%)

Company overview

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. Ibrexafungerp has also completed the Phase 3 CANDLE study for the prevention of recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Market cap
$23M
Employees
28
Headquarters
Jersey City, NJ
Website
scynexis.com
CEO
David Gonzalez Angulo
Listed
May 2, 2014
P/E
-1.02
Dividend yield
0.00%

Company financials

Revenue
$20.3M
Gross profit
$20.3M
Operating income
-$24.4M
EBITDA
-$20.2M
Net income
-$24.5M
EPS
-$3.60
Total assets
$77.6M
Total debt
$2.1M
Gross margin
100.00%
Net margin
-120.51%
Earnings yield
-98.36%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

3.344.615.897.168.43
SCYX 1D NASDAQ O3.99H4.00L3.85C3.85-0.09 (-2.41%)Vol18.37K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire
SCYXSCYNEXIS, Inc. Press release SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference GlobeNewswire
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases GlobeNewswire
SCYXSCYNEXIS, Inc. Press release SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek GlobeNewswire
SCYXSCYNEXIS, Inc. Stock news SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell? Defense World
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) GlobeNewswire
SCYXSCYNEXIS, Inc. Stock news Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX) Defense World
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 GlobeNewswire
SCYXSCYNEXIS, Inc. Stock news Adherex Technologies (NASDAQ:FENC) and SCYNEXIS (NASDAQ:SCYX) Financial Survey Defense World
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D. GlobeNewswire
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development GlobeNewswire
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer GlobeNewswire
SCYXSCYNEXIS, Inc. Press release SCYNEXIS to Participate in Upcoming Investor Conferences GlobeNewswire
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Announces One-for-Eight Reverse Stock Split GlobeNewswire
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire
SCYXSCYNEXIS, Inc. Stock news SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
SCYXSCYNEXIS, Inc. Press release SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
SCYXSCYNEXIS, Inc. Stock news SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript Seeking Alpha
SCYXSCYNEXIS, Inc. Press release Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million Business Wire
See more
FAQ

Questions about SCYNEXIS, Inc.

What does SCYNEXIS, Inc. do?
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. Ibrexafungerp has also completed the Phase 3 CANDLE study for the prevention of recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc.
What is SCYX's market cap?
SCYNEXIS, Inc. (SCYX) is a listed stock with a live quote. The latest market cap on this page is $23M.
Where is SCYNEXIS, Inc. headquartered?
SCYNEXIS, Inc. is headquartered in Jersey City, NJ.
How do I get SCYX news from the API?
Call GET /v1/news?tickers=SCYX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does SCYX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for SCYX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the SCYX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs